Non-Alcoholic Steatohepatitis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis – Pipeline Review, H1 2017’, provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis

The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects

The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Albireo Pharma Inc

Allergan Plc

Alnylam Pharmaceuticals Inc

Amunix Operating Inc

Aquinox Pharmaceuticals Inc

Ardelyx Inc

Arisaph Pharmaceuticals Inc

ARMO Biosciences Inc

AstraZeneca Plc

Betagenon AB

BioLineRx Ltd

BiOrion Technologies BV

Bird Rock Bio Inc

BLR Bio LLC

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd

Cardax Inc

Carmot Therapeutics Inc

Catabasis Pharmaceuticals Inc

Cerenis Therapeutics Holding SA

ChemoCentryx Inc

CohBar Inc

Conatus Pharmaceuticals Inc

Connexios Life Sciences Pvt Ltd

CymaBay Therapeutics Inc

Daiichi Sankyo Company Ltd

Dimerix Bioscience Pty Ltd

Dong-A Socio Holdings Co Ltd

DURECT Corp

Dynavax Technologies Corp

Eli Lilly and Company

Enanta Pharmaceuticals Inc

Exicure Inc

FORMA Therapeutics Inc

Galectin Therapeutics Inc

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc

Genextra Spa

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GRI Bio Inc

Hanmi Pharmaceuticals Co Ltd

iCo Therapeutics Inc.

Immuron Ltd

Intercept Pharmaceuticals Inc

Inventiva

Ionis Pharmaceuticals Inc

Jenrin Discovery Inc

Kissei Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Matinas BioPharma Holdings Inc

MedImmune LLC

Merck & Co Inc

Mitochon Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Naia Ltd

NeuroVive Pharmaceutical AB

NGM Biopharmaceuticals Inc

Nippon Chemiphar Co Ltd

Nitto Denko Corp

Novartis AG

NovaTarg Therapeutics Inc

Novo Nordisk A/S

Nuevolution AB

Pfizer Inc

Pharmaxis Ltd

Promethera Biosciences SA

ProMetic Life Sciences Inc

Protalix BioTherapeutics Inc

Regulus Therapeutics Inc

Saje Pharma LLC

Sancilio & Company Inc

Shire Plc

Stelic Institute & Co Inc

TaiwanJ Pharmaceuticals Co Ltd

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Vascular Biogenics Ltd

Verlyx Pharma Inc

Viking Therapeutics Inc

Virobay Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Non-Alcoholic Steatohepatitis - Overview 7

Non-Alcoholic Steatohepatitis - Therapeutics Development 8

Non-Alcoholic Steatohepatitis - Therapeutics Assessment 26

Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 41

Non-Alcoholic Steatohepatitis - Drug Profiles 83

Non-Alcoholic Steatohepatitis - Dormant Projects 372

Non-Alcoholic Steatohepatitis - Discontinued Products 374

Non-Alcoholic Steatohepatitis - Product Development Milestones 375

Appendix 386

List of Tables

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Albireo Pharma Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Allergan Plc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Alnylam Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Amunix Operating Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Aquinox Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Ardelyx Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Arisaph Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by ARMO Biosciences Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by AstraZeneca Plc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Betagenon AB, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by BioLineRx Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by BiOrion Technologies BV, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Bird Rock Bio Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by BLR Bio LLC, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Bristol-Myers Squibb Company, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Cardax Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Carmot Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Catabasis Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Cerenis Therapeutics Holding SA, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by ChemoCentryx Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by CohBar Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by CymaBay Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Dimerix Bioscience Pty Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by DURECT Corp, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Dynavax Technologies Corp, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Eli Lilly and Company, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Enanta Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Exicure Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by FORMA Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Galectin Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Galmed Pharmaceuticals Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Gemphire Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Genextra Spa, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Genfit SA, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by GenKyoTex SA, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Gilead Sciences Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by GRI Bio Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by iCo Therapeutics Inc., H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Immuron Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Intercept Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Inventiva, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Jenrin Discovery Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by MedImmune LLC, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Merck & Co Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Naia Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by NGM Biopharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Nippon Chemiphar Co Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Nitto Denko Corp, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Novartis AG, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by NovaTarg Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Novo Nordisk A/S, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Nuevolution AB, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Pfizer Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Pharmaxis Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Promethera Biosciences SA, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by ProMetic Life Sciences Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Protalix BioTherapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Regulus Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Saje Pharma LLC, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Sancilio & Company Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Shire Plc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Stelic Institute & Co Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Tiziana Life Sciences Plc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Vascular Biogenics Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Verlyx Pharma Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Viking Therapeutics Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Virobay Inc, H1 2017

Non-Alcoholic Steatohepatitis – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Non-Alcoholic Steatohepatitis – Dormant Projects, H1 2017

Non-Alcoholic Steatohepatitis – Dormant Projects, H1 2017 (Contd..1), H1 2017

Non-Alcoholic Steatohepatitis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports